Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04656041 · ClinicalTrials.gov registry record · Phase 2
Folfox+Irinotecan+Chemort In Esophageal Cancer
A Phase 2 study of Gastroesophageal Junction Adenocarcinoma and Esophagogastric Cancer, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT04656041: Recruiting Phase 2 study of Gastroesophageal Junction Adenocarcinoma and Esophagogastric Cancer, sponsored by Massachusetts General Hospital.
NCT04656041 is a Phase 2 study of Gastroesophageal Junction Adenocarcinoma and Esophagogastric Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 40 participants, below the 403-participant average among 40 other Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04656041, a Phase 2 study of Gastroesophageal Junction Adenocarcinoma and Esophagogastric Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: \- Liposomal irinotecan
Primary Outcome
All patients will undergo a full pathological review of their surgical specimen according to the AJCC Staging Classification, 6th. Initial gross evaluation and identification of resection margins will be performed jointly by the surgeon and the pathologist. Pathological complete response will be defined as the absence of any viable tumor cells within the pathologic specimen.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG FOLFOX/ nal-IRI
- RADIATION Proton Radiation Therapy
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth-Israel Deaconess Medical Center - Boston
- Massachusetts General Hospital at Newton Wellesley Hospital - Newton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT04656041 shows while recruiting
NCT04656041 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 403-participant average among 40 other Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Gastroesophageal Junction Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT04656041 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04656041 about?
NCT04656041 is a clinical study titled "Folfox+Irinotecan+Chemort In Esophageal Cancer". In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: \- Lip...
What is the current status of trial NCT04656041?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-06-29. Estimated completion is 2027-12.
What conditions does trial NCT04656041 study?
This clinical trial studies the following conditions: Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer.
What interventions are being tested in trial NCT04656041?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), FOLFOX/ nal-IRI (DRUG), Proton Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT04656041?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04656041 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Junction Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04656041's enrollment target sits among peer trials
40 32nd of 40 higher than 7 of 40 other Gastroesophageal Junction Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroesophageal Junction Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RECRUITING · Phase 2
-
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
RECRUITING · Phase 2
-
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI